Dosing &
Administration

CREON Has Dosing Strengths to Meet the Individual Lipase Needs of Your Patients1

CREON dosing should be
individualized for each patient.
Remember, the CREON dosage should
be
individualized and adjusted based
on
clinical symptoms, the degree of
steatorrhea present, and the
fat
content of the diet.1

CREON® (pancrelipase) dosing range and chart

12 months

>12 months
-30 lb

30-60 lb

60-110 lb

110+ lb

CREON Dosing Strengths

CREON® (pancrelipase) dosing at 3,000 lipase units

3,000

lipase units

CREON® (pancrelipase) dosing at 6,000 lipase units

6,000

lipase units

CREON® (pancrelipase) dosing at 12,000 lipase units

12,000

lipase units

CREON® (pancrelipase) dosing at 24,000 lipase units

24,000

lipase units

CREON® (pancrelipase) dosing at 36,000 lipase units

36,000

lipase units

Capsules shown are not actual size and do not represent the exact color shade. For illustrative purposes only.

The active ingredient in CREON evaluated in clinical trials is lipase.

Find the Right Dose for Your Patients

Use the CREON Per-meal Dosing Guide to calculate dosing for different patient types.

How to Dose CREON video

The CREON Dosing video makes it easy to understand appropriate dosing.

Video Transcript

Narrator:

Exocrine Pancreatic Insufficiency (or EPI) can result when the pancreas is damaged…

…due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.1

Not all patients with EPI are the same…

…and neither are their enzyme needs.

CREON has dosing strengths to meet patients’ individual lipase needs.2

So how do you find the right dose for YOUR patient?

Just remember “Weight, plate, titrate.”

CREON can be dosed by weight…

…and there are tools that help make the calculations — the dosing calculator on CREON.com…

…as well as the CREON dosing wheel…

…and the pocket dosing guide, available through your AbbVie representative.

For patients with EPI due to chronic pancreatitis or pancreatectomy, specific dosing may be appropriate.2 Visit CREON.com to view specific dosing recommendations for these patient populations.

It’s important to remind your patients that CREON should be taken with every meal and snack.2

For snacks, half of the prescribed CREON meal dose is usually recommended.2

It’s also important to remember that your patients’ initial starting dose and any dose increases should be individualized based on their2:

- clinical symptoms

- and the degree of steatorrhea

- and the fat content of their diet

For example, if patients are eating a diet that’s high in fat, you should consider increasing their enzyme dose accordingly.

Remind patients to set up a follow-up appointment in a few weeks to discuss how their therapy is working.

Ongoing conversations can help determine if dose adjustments may be needed.

Encourage your patients to share as much information as possible so that you can prescribe a dose that works for them.

Use the dosing calculator to help determine the proper dosage of CREON® (pancrelipase)

Determine an appropriate per-meal dose for your patients

Use Dosing Guide
Use the CREON® (pancrelipase) Treatment Tracker to help educate patients about their therapy

Encourage patients to track treatment and share the results with you

Download
Treatment Tracker
Request patient starter kits, product samples, and more

Request patient starter kits, product samples, and more

Contact a Rep

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. Reference:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.

back to top #tbd